Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Last trade$0.3401
Day change-$0.0463 (-11.98%)
Day range$0.336 – $0.402
Volume428,643
Market cap$5M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.2M
Price / earnings
—
Price / book
0.79×
Price / sales
0.19×
EV / sales
0.61×
EV / EBITDA
-0.73×
Profitability
Earnings per share
-$3.93
Return on assets
-153.3%
Return on equity
-792.44%
Dividend yield
0%
Liquidity and leverage
Debt / equity
2.35×
Current ratio
0.69×
Quick ratio
0.4×
Cash ratio
0.15×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.73M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for JAGX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$1.23M
$20.27M
$3.24M
$3.08M
$2.98M
$2.21M
$3.51M
$3.11M
Cost of revenue
$1.03M
$1.16M
$2.2M
$532K
$527K
$515K
$557K
$541K
Gross profit
$194K
$19.11M
$1.04M
$2.55M
$2.45M
$1.7M
$2.95M
$2.57M
Selling, general and administrative
$4.46M
$5M
$7.16M
$6.13M
$7.19M
$7.39M
$6.58M
$5.79M
Research and development
$3.34M
$3.93M
$14.31M
$3.66M
$3.27M
$3.73M
$4.53M
$4.04M
Total operating expenses
$7.79M
$8.93M
$21.48M
$9.79M
$10.46M
$11.12M
$11.11M
$9.83M
Operating income
-$7.6M
$10.18M
-$20.44M
-$7.24M
-$8.01M
-$9.42M
-$8.16M
-$7.26M
Interest expense
-$161K
-$699K
-$132K
-$6K
$15K
$56K
$110K
$162K
Income before taxes
-$12.8M
$8.72M
-$23.19M
-$9.65M
-$10.56M
-$10.6M
-$10.23M
-$10.02M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$12.8M
$8.72M
-$23.19M
-$9.65M
-$10.56M
-$10.6M
-$10.23M
-$10.02M
Net income attributable to common shareholders
-$12.7M
-$7.02M
-$23.2M
-$9.5M
-$10.41M
-$10.46M
-$9.92M
-$9.85M
EBITDA
-$7.12M
$10.66M
-$19.97M
-$6.76M
-$7.53M
-$8.94M
-$7.68M
-$6.79M
Basic earnings per share
-$235.50
-$204.00
-$2,022.19
-$2,997.27
-$5,384.10
-$8,766.75
—
-$12,547.50
Diluted earnings per share
-$235.50
-$204.00
-$2,022.19
-$2,997.27
-$5,384.10
-$8,766.75
—
-$12,547.50
Recent news
Company coverage with links to the original publishers.
Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now available for on-demand viewing for 90 days. Twenty companies across the life sciences sector presented at the forum, with select companies still accepting 1x1 management meeting requests through June 19th.
Toronto Star celebrates TIFF's 50th anniversary with a collector's edition magazine and photo exhibit featuring 50 iconic photographs by George Pimentel, highlighting the festival's cinematic history and star-studded moments.
Jaguar Health shares are falling after the company announced its phase 3 OnTarget trial results for crofelemer did not meet its primary endpoint. The stock has a float of only 4.889 million shares after a 1-for-60 reverse split.
Jaguar Health, a pharmaceutical company, has issued 455,000 shares of common stock to reduce its outstanding royalty balance by $1.85 million. This move is part of the company's strategy to manage its financial liabilities and streamline its capital structure.
Here's what you need to know about buying tech penny stocks in 2024
The post Picking Energy Penny Stocks, 3 Tips to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.